Mark Elliott Boulding, Executive VP AND CLO at PTC THERAPEUTICS, INC. (PTCT), sold 41,356 shares at $65.73 ($2.7M) on 2025-10-03, disclosed to the SEC on 2025-10-07.
Scheduled sale ($2.7M) by Executive VP AND CLO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $64.43 | 3,100 | $200K | 7.4% |
| 2 | $64.43 | 3,100 | $200K | 7.4% |
| 3 | $64.43 | 536 | $35K | 1.3% |
| 4 | $64.44 | 550 | $35K | 1.3% |
| 5 | $65.47 | 6,124 | $401K | 14.8% |
| 6 | $65.47 | 6,124 |
| $401K |
| 14.8% |
| 7 | $65.72 | 838 | $55K | 2.0% |
| 8 | $65.72 | 838 | $55K | 2.0% |
| 9 | $65.73 | 824 | $54K | 2.0% |
| 10 | $65.73 | 824 | $54K | 2.0% |
| 11 | $66.44 | 7,400 | $492K | 18.1% |
| 12 | $66.63 | 906 | $60K | 2.2% |
| 13 | $66.63 | 906 | $60K | 2.2% |
| 14 | $66.67 | 877 | $58K | 2.2% |
| 15 | $66.67 | 877 | $58K | 2.2% |
| 16 | $67.15 | 1,500 | $101K | 3.7% |
| 17 | $67.15 | 1,500 | $101K | 3.7% |
| 18 | $65.07 | 2,266 | $147K | 5.4% |
| 19 | $65.07 | 2,266 | $147K | 5.4% |
| Total | $65.66 avg | 41,356 | $2.7M | 100% |
| Filing → |
| PTCT | SELL | 2026-06-22 | $823K | — | Filing → |
| PTCT | SELL | 2026-05-19 | $203K | — | Filing → |
| PTCT | SELL | 2026-05-12 | $280K | — | Filing → |